Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin

What Was Tested

This randomized controlled trial paper looks at Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).

Post hoc analyses were performed to assess differences between responders and nonresponders.

Who Took Part

The abstract describes 12 individuals taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

In 2 phase III, randomized, double-blind studies, men and women with HIV-associated abdominal fat accumulation were randomly assigned (ratio, 2:1) to receive tesamorelin or placebo for 26 weeks.

At week 26, patients initially receiving tesamorelin were randomly assigned to continue receiving tesamorelin or to receive placebo for an additional 26 weeks.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Tesamorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the individuals nor the staff measuring them knew who was on Tesamorelin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Tesamorelin group a baseline to be compared against.

The methods mention a period of 26 weeks.

What Was Measured

PubMed files the paper under topics including Adiposity, Anti-HIV Agents, Growth Hormone-Releasing Hormone, HIV Infections, HIV-Associated Lipodystrophy Syndrome and Metabolome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) in 12 individuals over 26 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America), a journal based in United States.

More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.